Drug Combination Details
General Information of the Combination (ID: C88839) | |||||
---|---|---|---|---|---|
Name | Chrysin NP Info | + | Sorafenib Drug Info | ||
Structure |
![]() |
+ |
![]() |
||
Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib. | |||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Chrysin-induced ERK1/2 phosphorylation enhances the sensitivity of human gepatocellular carcinoma cells to sorafenib. |
References | ||||
---|---|---|---|---|
Reference 1 | Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib. Anticancer Res. 2019 Feb;39(2):695-701. |
![](/sites/default/files/kegg_pathway/hsa05200+5595.png)
![](/sites/default/files/kegg_pathway/hsa05200+5594.png)